Amgen Inc. (NASDAQ:AMGN) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript February 4, 2025 Amgen Inc. beats earnings expectations. Reported EPS is $5.31, expectations ...
Nasdaq17d
GLP-1 Drugs Cut Risk of Alzheimer's, NVO & LLY Shares Rise
In November 2024, Amgen announced 52-week top-line data from a phase II study on MariTide, its GIPR/GLP-1 receptor for obesity for obesity. The data showed that MariTide led to approximately 20% ...
Investing19d
FDA approves new colorectal cancer treatment
The company's investigational treatment for obesity and type 2 diabetes, MariTide, is of particular interest, with Phase 2 trial data expected in the second half of 2025. Analysts from Goldman Sachs ...
Insider Monkey20d
13 Highest Yielding Dividend Stocks in the Dow
The stock is down by over 11% in the past 12 months. The decline could be attributed to its leading weight loss candidate, MariTide, falling short of expectations in a mid-stage trial. Despite ...
Insider Monkey21d
15 Best NASDAQ Dividend Stocks To Buy
Amgen Inc. (NASDAQ:AMGN) is an American multinational biopharmaceutical company. Its MariTide has the potential to become a notable weight loss drug, and the company is also developing at least ...
MM&M21d
These CEOs want to market the next Ozempic. Just don’t call it that
Just ask Robert Bradway, Amgen chairman and CEO. At the J.P. Morgan Healthcare Conference this week, Bradway was asked what he sees as the pros and cons to Amgen’s experimental drug MariTide ...
Investing21d
Goldman Sachs retains Amgen buy stock rating on clinical trial
The conversation highlighted Amgen's confidence in MariTide, an investigational treatment for obesity and type 2 diabetes. The drug is noted for its potential monthly or less frequent dosing schedule ...